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We focused on apoptotic blebs from Leishmania major-infected macrophages as a vaccine for 30 
cutaneous leishmaniasis. Apoptosis was induced in Leishmania major-infected J774A.1 cells in 31 
order to prepare apoptotic blebs. Test groups of BALB/c mice were immunized with these at 32 
doses of 1 × 106, 5 × 106 or 1 × 107 blebs. An immunization control group received Leishmania 33 
lysate antigens. The results showed that as the number of apoptotic bodies increased, the 34 
lymphocyte proliferation index increased, and this was proportional to IFN-γ level in the test 35 
groups. Additionally, the difference of IFN-γ, IL-4, IFN-γ/IL-4 ratio, or total IgG (p < 0.0001) in 36 
all groups was statistically significant compared to the negative control group. The highest IFN-γ 37 
(514.0 ± 40.92 pg/mL) and IFN-γ/IL-4 ratio (2.94 ± 0.22) were observed in the group that 38 
received 1 × 107 apoptotic blebs. The highest levels of IL-4 (244.6 ± 38.8 pg/mL) and total IgG 39 
(5626 ± 377 μg/mL) were observed in the immunization control group. Reflecting these data, no 40 
lesions were observed in any of the groups vaccinated with apoptotic blebs after 12 weeks. In 41 
summary, the use of apoptotic blebs from Leishmania major-infected macrophages is protective 42 
against the challenge with Leishmania major in this animal model. 43 
 44 
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Apoptotic bleb; Cutaneous leishmaniasis; Leishmania major; Vaccination 46 
 47 




1. Introduction  50 
The Neglected Tropical Disease (NTD) leishmaniasis i  endemic in 98 countries affecting 51 
approximately 12 million people per year with 350 million people living at risk of disease (World 52 
Health Organization). Causative Leishmania species are sand fly borne kinetoplastid parasitic 53 
protozoa [1] and infection can lead to a wide spectrum of clinical pathologies, from self-healing 54 
but scarring cutaneous leishmaniasis (CL) to fatal visceral disease (VL). Amongst other factors, 55 
this diversity of disease is dependent on the parasite species, host immunity, and genetic 56 
background [2]. Largely due to elimination efforts in south Asia, the global burden of VL has 57 
decreased substantially in the past decade. However, du  to forced migration, the cases of CL 58 
have substantially increased in the same period [3]. Approximately, 75% of reported CL cases 59 
occur in 10 countries with an incidence rate of 0.7-1.3 million cases annually. However, the 60 
actual prevalence of this disease is estimated to be 6 to 10 times higher [4, 5].  61 
Controlling reservoirs and vectors, providing diagnostics and treatment, and the emergence 62 
of drug-resistant species are serious challenges for the control of CL. These issues illustrate the 63 
need for new drugs for CL or effective vaccines [6-8]. There are three generations of vaccine 64 
used against leishmaniasis, 11 of which entered in clinical trials. These include Leishvaccine, 65 
ALM, Leishmune, CaniLeish, and GALM for first generation, LEISH-F1, LEISH-F2, LEISH-F3, 66 
Leish-Tec, and SMTγ+NHµ for second generation, and ChAd63-KH for third generation. Among 67 
these, Leishmune®, CaniLeish®, and Leish-Tec were approved to be used as vaccine in animal 68 
[9]. Therefore, there is still no appropriate vaccine available for human use.  69 
In Iran in the 1970s and 1980s vaccination against CL widely used intradermal inoculation of 70 
live promastigotes of L. major (2-3 × 105), leishmanization. However, this practice was 71 
4 
 
discontinued due to drawbacks such as ulcer development in a few susceptible individuals [10]. 72 
Immunity on leishmanization has been proposed to be due to vaccinated people harboring live 73 
parasites in their skin which release excretory/secretory antigens (ESAs), stimulating the host 74 
immune system and induce protection [11]. Accordingly, researchers have focused on 75 
Leishmania spp. ESAs as vaccine targets [12]. However, it is now known that the protective 76 
immunity against L. major is related to immune system memory, not the parasite presence in the 77 
skin tissue [13, 14]. In light of this, studies have focused on several types of vaccine, including 78 
live or live-attenuated parasites, the whole killed parasites, Leishmania spp. antigens and naked 79 
DNA-encoding parasite antigens. However, none so far have had the efficacy to be developed for 80 
use as a vaccine in humans [15, 16]. Against this backdrop, we focused on a new approach to 81 
vaccination against CL: apoptotic blebs from Leishmania major-infected macrophages.  82 
Apoptotic blebs/bodies contain phosphatidylserine ad phosphorylcholine on their surface, 83 
facilitating the clearance of these bodies by antige  presenting cells such as macrophages [17]. 84 
After phagocytosis of an apoptotic bleb, the antigen presenting cells process and present 85 
antigenic epitopes to the adaptive immune cells on class I and class II major histocompatibility 86 
complex (MHC-I and -II) molecule. However, there is preferential antigen presentation on MHC-87 
I and therefore the cell-mediated immune response i timulated, this is important for an effective 88 
CL vaccine [18-21]. Therefore, in this study we evaluated apoptotic blebs from Leishmania 89 
major-infected macrophages as a vaccine candidate for CL in a murine model.  90 
 91 
2. Materials and Methods 92 
2.1. Leishmania maintenance 93 
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Leishmania major (MRHO/IR/75/ER) was used in the present study. Promastigotes were cultured 94 
and maintained in RPMI-1640 medium (Gibco, Grand Island, NY, USA) supplemented by fetal 95 
bovine serum (FBS; Gibco, Grand Island, NY, USA) and penicillin-streptomycin solution (pen-96 
strep; 100 IU/mL penicillin and 100 μg/mL streptomycin; Sigma-Aldrich, Missouri, USA). In97 
order to reduce the proliferation of the parasite and to maintain it without passage for about 2 98 
months, the amount of FBS was adjusted to 2% and the number of parasites to 10,000/mL. In 99 
addition, the culture medium containing the parasite was incubated at 24 °C for 24 hours and then 100 
kept at 4 °C for long-term maintenance. Daily monitring of the growth of the parasite and the 101 
absence of fungal and bacterial contamination was undertaken [22].  102 
 103 
2.2. Animal model 104 
8-10 week-old female BALB/c mice (Pasteur Institute, T hran, Iran), 20-25 gram, were utilized. 105 
The project underwent ethical review and was approved by the Ethics Committee of Mazandaran 106 
University of Medical Sciences (Code: IR.MAZUMS.REC.1397.315). The care and use of 107 
experimental animals complied with local animal welfare laws, guidelines, and policies. 108 
 109 
2.3. Apoptosis induction in Leishmania major-infected macrophages  110 
The cell line macrophages (J774A.1) were cultured in the same medium as used for the parasite 111 
culture but with 20% FBS as complete medium. 2 × 106 cells, counted using a Neubauer 112 
haemocytometer, were added to each 75 cm2 ell culture flask (Corning, Oneonta, NY, USA), 113 
containing 10 mL of the complete medium. The flasks were incubated at 37 °C, 5% CO2, and 114 
95% humidity for 5-7 days (80% confluent, approximately 9.4 × 106 cells per flask) and 10 115 
stationary phase promastigotes per macrophage (9.4 × 107) were added. The infection rate of 116 
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macrophage was calculated as 90.7% to 92.8%. After a fu ther 24 hour incubation, apoptosis was 117 
induced in the infected cells using the Apoptosis Inducer Kit (Abcam, Cambridge, UK) according 118 
to the manufacturer’s instruction. Afterwards, the suspensions obtained were filtered using a 5 119 
μm pore size membrane filter (Corning, Oneonta, NY, USA) and some of the solution was 120 
cultured and the parasite did not grow in the medium. The solution was centrifuged at 20,000 ×g 121 
for 15 minutes, the supernatants were discarded, and 1 mL of normal saline (0.85% w/v NaCl) 122 
was added to the precipitate. Following evaluation as below, the suspension of apoptotic blebs 123 
was stored at -20 °C until use. 124 
 125 
2.4. Differentiation of apoptotic- from necrotic bodies by flow cytometry 126 
The Annexin V-FITC Apoptosis Staining/Detection Kit (Abcam, Cambridge, UK) was used to 127 
differentiate apoptotic from necrotic bodies. The reaction mixtures were prepared according to 128 
manufacturer’s instruction and read using as Coulter® Epics XL-MCL™ Flow Cytometer 129 
(Beckman Coulter, Fullerton, CA, USA). Briefly, four situations could occur: intact living cells 130 
which do not stain with both annexin V and PI; early poptotic cells that stain with annexin V but 131 
do not stain with PI; late apoptotic cells that stain with both annexin V and PI; and necrotic cells 132 
that stain with PI but not annexin V.  133 
 134 
2.5. Apoptotic blebs examination using scanning electron microscope (SEM) 135 
The apoptotic bleb-containing solution were affixed to the surface of a metal stub, coated with 136 
gold through a SEM sputter coater (Bio-Rad, West Chester, PA, USA) and examined using 137 
Hitachi S-4300 SEM (Hitachi Science Systems, Tokyo, Japan) at accelerating voltages between 5 138 




2.6. Preparation of Leishmania lysate antigens  141 
As an immunization control, Leishmania lysate antigens (LLAs) were prepared by lysis of L. 142 
major promastigotes. 1 × 109 promastigotes in 5 mL of normal saline were lysed by bead-beating 143 
using 0.5 mm diameter glass beads (Sigma, Tokyo, Japan), 2 mL of beads were added to the 144 
suspension and this was vortexed vigorously for 5 minutes in 1 minute cycles with 10 seconds on 145 
ice between. The resulting lysate was passed throug a 0.22 μm pore size membrane filter 146 
(Corning, Oneonta, NY, USA), and the protein concentration was measured by the Bradford 147 
method [23]. The LLAs solution was stored at -20 °C until use.  148 
 149 
2.7. Immunization of mice 150 
55 BALB/c mice were randomly divided into 5 groups of 11, of which three test groups received 151 
1 × 106, 5 × 106 or 1 × 107 apoptotic blebs, prepared above, in 0.5 mL of normal saline. One of 152 
the two remaining groups was considered as immunization control and received 100 μg of LLAs, 153 
the remaining group served as the negative control and received 100 μL of normal saline. The 154 
groups were subcutaneously inoculated twice at intervals of 14 days.  155 
 156 
2.8. Cytokine and antibody assay 157 
2 weeks after the second injection, approximately 300 μL of blood was taken from the tail of the 158 
mice. The samples were centrifuged at 2000 ×g, 4 °C, for 10 minutes, the serum was separated 159 
and kept at -20 °C until use. Mouse IFN Gamma PicoKine™ ELISA Kit, Mouse IL-4 PicoKine 160 
™ ELISA Kit, and Mouse Total IgG PicoKine ™ ELISA (BosterBio, Wuhan, China) were used 161 
to measure the levels of IFN-γ, IL-4 and total IgG respectively in the serum samples according to 162 
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the manufacturer’s protocol. The reactions were analyzed using Bio-Rad Model 680 Microplate 163 
Reader (Bio-Rad, Hercules, CA, USA) and the value from each sample was calculated according 164 
to the plotted standard curve provided in the kits. 165 
 166 
2.9. Lymphocyte proliferation assay  167 
24 hours after blood sampling, 5 mice from each group were randomly selected and euthanized. 168 
Subsequently, 5 ml of normal saline was immediately injected into the peritoneal cavity of each 169 
mouse and the leukocytes containing peritoneal fluid were harvested. To isolate lymphocytes 170 
from peritoneal macrophages the cell suspension of each mouse was poured into separate 12.5 171 
cm2 cell culture flasks (Corning, Oneonta, NY, USA) and i cubated at 37 °C, 5% CO2, and 95% 172 
humidity for 3 hours. The supernatants, containing lymphocytes, were then harvested and 173 
centrifuged at 400 ×g, 4 °C for 10 min. The supernata ts were discarded and 1 mL of phenol red 174 
free RPMI-1640 with pen-strep and 5% FBS was added to the precipitates. For each mouse 5 × 175 
105 lymphocytes, in 100 μL of media, were added into 9 wells of a 96-well microplate 176 
(BrandTech Scientific, Essex, CT, USA). 10 μg of LLAs was added to three wells as the 177 
immunization control and the mitogen PHA (2.5 μg/mL) was added to three as the control for 178 
normalization [24]. The remaining three wells were considered the negative control and nothing 179 
was added. The final volume of each well was adjusted to 150 μL using media. The plates were 180 
incubated at 37 °C, 5% CO2, and 95% humidity for 48 hours. Subsequently, 20 μL of MTT stock 181 
solution (5 mg/mL; Gibco, Carlsbad, CA, USA) was adde  to each well and the volume adjusted 182 
to 200 μL using the medium (final concentration of MTT was 0.5 mg/mL). The plates were 183 
incubated as above for 4 hours and then centrifuged at 400 ×g for 10 minutes. The supernatants 184 
were discarded and 100 μL of acidic dimethyl sulfoxide (DMSO 1% of 1N HCl; Sigma-Aldrich, 185 
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Missouri, USA) was added to each well. The wells were rotated gently for 10 minutes using 186 
shaking incubator (Eppendorf, Hamburg, Germany), centrifuged at 10,000 ×g for 5 minutes and 187 
the supernatants were collected and analyzed using a scanning multiwell spectrophotometer 188 
(Biotek, Burlington, VT, USA) at the wavelength of 540 nm. The obtained optical densities 189 
(ODs) were analyzed according the following formula: 190 
Firstly, for each mouse the stimulation index (SI) of lymphocytes was calculated for the treated 191 
lymphocytes with LLAs and PHA as follows: 192 
SI (LLA): 
  	 
    	 
  
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  194 
NC is negative control 195 
Then:  196 
∆SI = SI (LLA) - SI (PHA) 197 
The mean ∆SI was calculated for each group of 5 mice.  198 
Finally, the proliferation index (PI) was calculated: 199 
PI = 2(∆ 	 
 

    ∆ 	 
  ) 200 
NC is the negative control group (i.e. untreated mouse group); the treated group is each of the 201 
mice groups treated with apoptotic blebs or LLA.  202 
PI indicates the potency of lymphocyte proliferation in response to injection of each treated 203 
group.  204 
 205 
2.10. Infection challenge 206 
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The 6 mice which remained in each group were utilized in a challenge experiment [25]. 5 × 105 207 
stationary phase promastigotes in a 10-μL volume were inoculated intradermally 3-4 mm from 208 
the base of the tail of the mice. The mice were monitored weekly for 12 weeks for lesion 209 
development. The formula used in our study was that for ellipsoid lesions [26]:  210 
LS = ([A 2 × B/2 ⁄ × C/2]  × 4/3π)  211 
Where LS is the lesion size in mm3; “A” is depth of the lesion in mm; “B” and “C” respectively 212 
are the width and length of the lesion in mm.  213 
 214 
2.11. Data analyses 215 
Shapiro-Wilk statistical test was used to measure no mal distribution of data. Data were analyzed 216 
using IBM SPSS v16 software (IBM Corp., Armonk, NY, USA) based on the two-tailed t-test 217 
and analysis of variance (ANOVA) statistical methods. In addition, post hoc comparison was 218 
performed between groups using the Tukey’s HSD test. The statistical differences were 219 
considered significant where p value < 0.05. The ELISA data were analyzed using GraphPad 220 
Prism v6 software (GraphPad, La Jolla, CA, USA).  221 
 222 
3. Results   223 
3.1. Quantity and quality of apoptotic blebs from Leishmania major-infected macrophages 224 
The blebs were quantified using flow cytometry. 86.6% of the bodies identified were apoptotic, 225 
of which 30.1% were early apoptotic bodies and 56.5% were late apoptotic bodies. The total 226 
number of these bodies was 20,606,700 per mL (Figure 1).  227 
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The quality of the apoptotic bodies was established using SEM. The average size was 3.88 228 
μm (95% CI 2.69-5.07), and the bodies were uniform and slightly oval (> 98%) in shape. All had 229 
an intact cell membrane (Figure 2). 230 
 231 
3.2. Cytokine and antibody assay 232 
IFN-γ, IL-4, and total IgG levels were assessed in the serum samples from the immunized 233 
mice. Statistical analyses, using ANOVA, showed that ere was a significant difference for the 234 
levels of each of total IgG, IFN-γ and IL-4, as well as the IFN-γ/IL-4 ratio, among the groups of 235 
mice (p < 0.0001) (Table 1). Moreover, the pairwise comparison between the groups is shown in 236 
Table 2. In addition, the lowest levels of total IgG (1522 ± 327 μg/mL), IFN-γ (153.1 ± 27.3 237 
pg/mL), IL-4 (135.3 ± 28.5 pg/mL), and the lowest IFN-γ/IL-4 ratio (1.13 ± 0.07) were observed 238 
in the negative control group. The highest level of IFN-γ (514.0 ± 40.92 pg/mL) and IFN-γ/IL-4 239 
ratio (2.94 ± 0.22) was observed in the group that received 1 × 107 apoptotic blebs (maximum 240 
dose). The highest levels of IL-4 (244.6 ± 38.8 pg/mL) and total IgG (5626 ± 377 μg/mL) were 241 
observed in the immunization control group (Figure 3). 242 
 243 
3.3. Lymphocyte proliferation assay 244 
The proliferation index of the three groups that received apoptotic blebs and the 245 
immunization control LLA group, was calculated relative to the negative control group (∆SI = -246 
1.1). The lowest proliferation index was observed for the group that received 1 × 106 apoptotic 247 
blebs (8.75) and the highest (24.25) was for the group that received 1 × 107 apoptotic blebs 248 




3.4. Lesion size evaluation 251 
No lesion development was observed in any of the groups that received apoptotic blebs. 252 
However, lesion development was observed in the mice from the negative and immunization 253 
control LLA groups. Maximum lesion size was 11.7 ± 1.03 mm3 in the negative control group 254 
and 5.89 ± 0.19 mm3 in the immunization control group at the 12th week. The mean ± standard 255 
deviation of the lesion size in mm3 in the mice of the negative and immunization contrl groups 256 
from week 1 to week 12 is shown in Figure 5. There was a statistically significant difference 257 
between the negative control group and each of the groups received apoptotic blebs (p < 0.0001). 258 
Moreover, a significant statistical difference was observed between the immunization control 259 
group and each of the groups received apoptotic blebs (p < 0.001).  260 
 261 
4. Discussion 262 
There are many challenges for the development of a CL vaccine, including the genetic 263 
diversity in human populations and in the species and strains of Leishmania parasite, the type of 264 
vaccine, dose of vaccine, and route of vaccine administration [27]. The purpose of the 265 
vaccination is the development of immunological memory, and both CD4+ and CD8+ T cells are 266 
important for the immunity against L. major. Therefore, it is clear that an effective vaccine 267 
should not only be safe and easily available but also should be capable of supporting the 268 
prolonged induction of CD4+ and CD8+ T lymphocytes [28].  269 
The lymphocyte proliferation test is a non-specific test used to evaluate the lymphocyte 270 
response to specific antigens and is useful to evaluate the efficacy of a vaccine [29, 30]. In the 271 
reported study, it was observed that as the number of apoptotic bodies increased, the lymphocyte 272 
proliferation index increased and this was proportional to IFN-γ measured in the test groups. 273 
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Previously, the lymphocyte proliferation response was used to assess three parasitic antigens as 274 
vaccines, the lowest proliferation index was observed in the LLAs injected group and this was 275 
consistent with the measured IFN-γ [31]. Therefore, lymphocyte proliferation is an indicator of 276 
the cellular immune response, especially IFN-γ production [32].  277 
One component of a vaccine is usually an adjuvant to enhance specific immune responses 278 
and increase vaccine efficacy. L. major ribosomal protein (LRP) was evaluated as a vaccine alone 279 
or in combination with CpG oligodeoxynucleotides (CpG-ODN) as an adjuvant. Injection of the 280 
vaccine with the adjuvant (LRP+CpG) significantly increased the IFN-γ response in splenocyte 281 
supernatants of the mice whilst considerably decreasing the amount of IL-4 and IL-10, with IFN-282 
γ/IL-10 ratio ~ 40 and IFN-γ/IL-4 ratio ~ 100 [33]. This IFN-γ/IL-4 ratio is much larger than 283 
IFN-γ/IL-4 ratio of the group that received 1 × 106 the apoptotic blebs (95% CI 1.37-1.45) in the 284 
reported study. Iborra, Parody [33] showed that the immune responses prevented the formation of 285 
lesions in the challenged BALB/c mice; however, some swelling was observed in the LRP+CpG 286 
vaccinated mice and the few parasites were found in the tissue. In the reported study, no lesions 287 
were observed in the challenged mice received apoptotic blebs, precluding the measurement of 288 
parasite burden.  289 
Few adjuvants are acceptable for human use, and there ar  many limitations to introducing a 290 
new one [34]. Interestingly, apoptotic blebs can be both a vaccine and an adjuvant in that foreign 291 
antigen containing apoptotic bodies act as natural adjuvants that stimulate a specific cellular 292 
immune response mediated by CD8+ T cell, enhancing the vaccine efficacy and providing stable 293 
immunity [35-37]. The results of the reported study support this approach, however, to evaluate 294 
the role of host factors in the induction of immunity observed in this study, future work will need 295 
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to analyze the effects of apoptotic blebs from uninfected macrophages on the induction of an 296 
immune response. 297 
LLAs-loaded liposomes have also resulted in an improved, although non-protective, immune 298 
response, which increased IFN-γ and reduced IL-4 compared to LLAs alone [38]. The highest 299 
amount of total IgG was quantified in the LLAs alone group [38]. Similarly, in the reported 300 
study, the highest level of total IgG was observed in the LLAs group, consistent with the high 301 
level of IL-4. Furthermore, LLAs have been shown to induce a higher IgG response than 302 
recombinant Leishmania homolog of receptors for activated C-kinase (rLACK) antigens in 303 
BALB/c mice [39]. An increase in the amount of IFN-γ level and a decrease in IL-10 level were 304 
also observed in splenocyte supernatants of the rLACK group compared to the LLAs group, with 305 
an IFN-γ/IL-10 ratio of 55 for the rLACK group compared to 15.3 for LLAs. This indicated more 306 
potent cellular immune response to rLACK, however, this response was not protective against L. 307 
major challenge [39]. Similarly, in the reported study, IgG and IL-4 were higher in the LLAs 308 
group than in the test groups (i.e. the received apoptotic blebs). However the IFN-γ/IL-4 ratio for 309 
rLACK (~ 329) was very much larger than in the apoptotic blebs test groups (1.41-2.94 310 
depending on dose), despite protective immunity being observed in the latter but not the former.  311 
The quantity of IFN-γ produced on vaccination is considered to be the most important factor 312 
in the development of a protective immune response against CL [40, 41]. Interestingly, despite 313 
the lack of lesion growth in the groups that received apoptotic blebs, IFN-γ response in the mouse 314 
sera was much lower than that obtained in other studies that found no protection against 315 
challenge [38, 39]. To evaluate the effect of IFN-γ on preventing lesion development, IL-12 316 
together with L. braziliensis was inoculated into a murine model and a significant increase in 317 
IFN-γ was observed. However, this did not prevent L. brasiliensis lesion development [42]. 318 
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Consequently, it can be concluded that factors other than the quantity of IFN-γ and IL-4, and the 319 
IFN-γ/IL-4 ratio, are central to the development of a protective immune response for CL.  320 
Clearly our understanding of IFN-γ and IL-4 function in CL is incomplete, IL-4 and IL-4RA 321 
knockout mice are rendered susceptible to challenge with L. major [43]. Furthermore, it is 322 
expected that during the lesion healing, IL-4 will be reduced and IFN-γ increased, however the 323 
expression level IL-4 in the margin of the late lesion  was found be to higher than IFN-γ [44].  324 
 325 
5. Conclusions 326 
In the presented study, apoptosis was induced in Leishmania-infected macrophages and the 327 
apoptotic-blebs collected. These bodies will contain fragments of the parasite and together can 328 
function as analogous to a whole L ishmania. Whilst the mechanism of inducing protective 329 
immune response has not been evaluated for the apoptotic-blebs from Leishmania major-infected 330 
macrophages in the current study, it is likely that t ese ‘fragments’ constitute a complex antigenic 331 
picture necessary for immunity. The results showed that vaccination with even the lowest number 332 
(1 × 106) tested of these apoptotic-blebs, is protective against L. major challenge. In addition, we 333 
propose that a factor other than the quantity of IFN-γ and the IFN-γ/IL-4 ratio is likely to play a 334 
role in providing this protection, this will be the focus of future studies.  335 
 336 
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Table 1. The results of ANOVA statistical test for ELISA data in the examined groups 457 
 458 
a AB 1: the group that received 1 × 106 apoptotic blebs from Leishmania major-infected macrophages   459 
b AB 2: the group that received 5 × 106 apoptotic blebs from Leishmania major-infected macrophages   460 
c AB 3: the group that received 1 × 107 apoptotic blebs from Leishmania major-infected macrophages   461 
d PC: the immunization control group that received L ishmania lysate antigens 462 
e NC: the negative control group 463 
 464 
 465 
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a Mean difference shown 473 
b AB 1: the group that received 1 × 106 apoptotic blebs from Leishmania major-infected macrophages   474 
c AB 2: the group that received 5 × 106 apoptotic blebs from Leishmania major-infected macrophages   475 
d AB 3: the group that received 1 × 107 apoptotic blebs from Leishmania major-infected macrophages   476 
e PC: the immunization control group that received L ishmania lysate antigens 477 
f NC: the negative control group  478 
* p < 0.05 479 
**  p < 0.01 480 
***  p < 0.001 481 
****  p < 0.0001 482 
IFN-γ (pg/mL) AB 1 AB 2 AB 3 PC NC  IL-4 (pg/mL) AB 1 AB 2 AB 3 PC NC 
AB 1b 0 8.09 252.1****  17.73 108.8****   AB 1 0 8.36 9.18 60.45***  48.91**  
AB 2c  0 244.0****  9.63 116.9****   AB 2  0 0.81 68.82****  40.55* 
AB 3d   0 234.4****  360.9****   AB 3   0 69.64****  39.73* 
PCe    0 126.5****   PC    0 109.4****  
NCf     0  NC     0 
             
IFN-γ/IL-4 ratio AB 1 AB 2 AB 3 PC NC  IgG (μg/mL) AB 1 AB 2 AB 3 PC NC 
AB 1 0 0.08 1.53****  0.27****  0.28****   AB 1 0 709.7***  916.2****  2558****  1546****  
AB 2  0 1.44****  0.36****  0.37****   AB 2  0 206.5 1849****  2256****  
AB 3   0 1.8****  1.81****   AB 3   0 1642****  2463****  
PC    0 0.007  PC    0 4105****  




Figure legends: 484 
Figure 1. Detection of apoptotic blebs using flow cytometry. Q1: necrotic bodies; Q2: late 485 
apoptotic; Q3: live cells; Q4: early apoptotic. The scales represent relative intensity of 486 
fluorescence for each of the two fluorophores. The sample was diluted to one-sixtieth 487 
 488 
Figure 2. Detection of apoptotic blebs using scanning electron microscope (SEM) 489 
 490 
Figure 3. The amount of IFN-γ, IL-4, IFN-γ/IL-4 ratio, and total IgG in the serum samples of the491 
examined mice. AB 1: the group that received 1 × 106 apoptotic blebs from Leishmania major-492 
infected macrophages; AB 2: the group that received 5 × 106 apoptotic blebs from Leishmania 493 
major-infected macrophages; AB 3: the group that received 1 × 107 apoptotic blebs from 494 
Leishmania major-infected macrophages; PC: the immunization control gr up that received 495 
Leishmania lysate antigens; NC: the negative control group  496 
 497 
Figure 4. Proliferation index of lymphocytes in the treated groups relative to the negative control 498 
group. AB 1: the group that received 1 × 106 apoptotic blebs from Leishmania major-infected 499 
macrophages; AB 2: the group that received 5 × 106 apoptotic blebs from Leishmania major-500 
infected macrophages; AB 3: the group that received 1 × 107 apoptotic blebs from Leishmania 501 
major-infected macrophages; PC: the immunization control gr up that received Leishmania 502 




Figure 5. The process of lesion formation from the beginning to the end of the examination. (A) 505 
Lesion size in the negative and immunization control gr ups. (B) Top-left picture shows the 506 
lesion in the negative control group. Top-right picture shows the lesion in the immunization 507 
control group. The two pictures below show that the mice receiving apoptotic bodies did not 508 











• No lesions were observed in the groups vaccinated with apoptotic blebs from Leishmania 
major-infected macrophages 
• Apoptotic blebs contain a wide variety of the parasite antigens and may stimulate immune 
responses similar to whole killed parasite 
• The highest IFN-γ and IFN-γ/IL-4 ratio were observed in the group that received 1 × 107 
apoptotic blebs 
• The immunization with apoptotic blebs protected mice from cutaneous swelling against 
Leishmania major challenge 
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